Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gain Therapeutics Inc (GANX)

Gain Therapeutics Inc (GANX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 81,949
  • Shares Outstanding, K 42,242
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,160 K
  • EBIT $ -19 M
  • EBITDA $ -19 M
  • 60-Month Beta 0.11
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.73

Options Overview Details

View History
  • Implied Volatility 191.59% (-27.42%)
  • Historical Volatility 146.22%
  • IV Percentile 39%
  • IV Rank 20.22%
  • IV High 810.99% on 12/10/25
  • IV Low 34.58% on 09/04/25
  • Expected Move (DTE 15) 0.3825 (19.72%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 231
  • Volume Avg (30-Day) 574
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 11,947
  • Open Int (30-Day) 14,439
  • Expected Range 1.5575 to 2.3225

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.13
  • Number of Estimates 2
  • High Estimate $-0.13
  • Low Estimate $-0.13
  • Prior Year $-0.16
  • Growth Rate Est. (year over year) +18.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7300 +12.14%
on 03/30/26
3.0699 -36.81%
on 03/06/26
-0.6700 (-25.67%)
since 02/27/26
3-Month
1.6100 +20.50%
on 02/05/26
3.2900 -41.03%
on 01/02/26
-1.2800 (-39.75%)
since 12/31/25
52-Week
1.4100 +37.59%
on 08/01/25
4.3400 -55.30%
on 12/11/25
+0.1300 (+7.18%)
since 04/01/25

Most Recent Stories

More News
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update

BETHESDA, Md., March 26, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development...

GANX : 1.9400 (unch)
Gain Therapeutics to Present at the 38th Annual ROTH Conference

BETHESDA, Md., March 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development...

GANX : 1.9400 (unch)
Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026

Additional biomarker analysis reveals higher CSF levels of DOPA decarboxylase (DDC – an emerging PD biomarker) at baseline with a reduction following 90 days of dosing with GT-02287 in individuals with...

GANX : 1.9400 (unch)
Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update

Interim analysis of Phase 1b clinical study of GT-02287, including biomarker and clinical endpoints, will be presented in oral symposium Company remains on track to initiate Phase 2 clinical trial...

GANX : 1.9400 (unch)
Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

BETHESDA, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development...

GANX : 1.9400 (unch)
Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week

BETHESDA, Md., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development...

GANX : 1.9400 (unch)
Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287

BETHESDA, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development...

GANX : 1.9400 (unch)
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease

BETHESDA, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development...

GANX : 1.9400 (unch)
Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease

Results showed CNS target engagement with reduction in GCase substrate glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF), a prespecified endpoint The reduction in GluSph in CSF, a first-ever...

GANX : 1.9400 (unch)
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025

GT-02287 reduces mitochondrial stress and enhances neuronal survival in MPP+ treated rat dopaminergic neurons GT-02287 decreases staining for MIRO1, suggesting improved mitochondrial health in α-synuclein-induced...

GANX : 1.9400 (unch)

Business Summary

Gain Therapeutics Inc. is redefining drug discovery with its See-Tx(TM) target identification platform. It involved in identifying and optimizing allosteric binding sites which have never before been targeted. The company is unlocking new treatment options for difficult-to-treat disorders characterized...

See More

Key Turning Points

3rd Resistance Point 2.1567
2nd Resistance Point 2.0933
1st Resistance Point 2.0167
Last Price 1.9400
1st Support Level 1.8767
2nd Support Level 1.8133
3rd Support Level 1.7367

See More

52-Week High 4.3400
Fibonacci 61.8% 3.2207
Fibonacci 50% 2.8750
Fibonacci 38.2% 2.5293
Last Price 1.9400
52-Week Low 1.4100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.